CAPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CAPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-09), Capricor Therapeutics's current share price is $5.24. Capricor Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $1.41. Capricor Therapeutics's Cyclically Adjusted PS Ratio for today is 3.72.
The historical rank and industry rank for Capricor Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Capricor Therapeutics's highest Cyclically Adjusted PS Ratio was 9.40. The lowest was 0.24. And the median was 2.88.
CAPR's Cyclically Adjusted PS Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Capricor Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.156. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.41 for the trailing ten years ended in Mar. 2024.
The historical data trend for Capricor Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capricor Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 2.78 | 3.17 | 2.28 | 3.26 | 4.80 |
For the Biotechnology subindustry, Capricor Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Capricor Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Capricor Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 5.24 | / | 1.41 | |
= | 3.72 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capricor Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Capricor Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.156 | / | 131.7762 | * | 131.7762 | |
= | 0.156 |
Current CPI (Mar. 2024) = 131.7762.
Capricor Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.891 | 100.560 | 1.168 |
201409 | 0.891 | 100.428 | 1.169 |
201412 | 0.890 | 99.070 | 1.184 |
201503 | 0.701 | 99.621 | 0.927 |
201506 | 0.562 | 100.684 | 0.736 |
201509 | 0.561 | 100.392 | 0.736 |
201512 | 0.560 | 99.792 | 0.739 |
201603 | 0.551 | 100.470 | 0.723 |
201606 | 0.508 | 101.688 | 0.658 |
201609 | 0.374 | 101.861 | 0.484 |
201612 | 0.319 | 101.863 | 0.413 |
201703 | 0.412 | 102.862 | 0.528 |
201706 | 0.450 | 103.349 | 0.574 |
201709 | 0.134 | 104.136 | 0.170 |
201712 | 0.181 | 104.011 | 0.229 |
201803 | 0.149 | 105.290 | 0.186 |
201806 | 0.139 | 106.317 | 0.172 |
201809 | 0.072 | 106.507 | 0.089 |
201812 | 0.209 | 105.998 | 0.260 |
201903 | 0.069 | 107.251 | 0.085 |
201906 | 0.119 | 108.070 | 0.145 |
201909 | 0.038 | 108.329 | 0.046 |
201912 | 0.051 | 108.420 | 0.062 |
202003 | 0.027 | 108.902 | 0.033 |
202006 | 0.003 | 108.767 | 0.004 |
202009 | 0.001 | 109.815 | 0.001 |
202012 | 0.003 | 109.897 | 0.004 |
202103 | 0.002 | 111.754 | 0.002 |
202106 | 0.009 | 114.631 | 0.010 |
202109 | 0.000 | 115.734 | 0.000 |
202112 | 0.000 | 117.630 | 0.000 |
202203 | 0.000 | 121.301 | 0.000 |
202206 | 0.000 | 125.017 | 0.000 |
202209 | 0.065 | 125.227 | 0.068 |
202212 | 0.038 | 125.222 | 0.040 |
202303 | 0.118 | 127.348 | 0.122 |
202306 | 0.155 | 128.729 | 0.159 |
202309 | 0.240 | 129.860 | 0.244 |
202312 | 0.394 | 129.419 | 0.401 |
202403 | 0.156 | 131.776 | 0.156 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Capricor Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
David B Musket | director | C/O CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK CA 94025 |
Collier Earl M Jr | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Paul Gisbert Auwaerter | director | C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121 |
Mike Kelliher | director | C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121 |
Philip J Gotwals | director | C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121 |
Xavier Avat | officer: CHIEF BUSINESS OFFICER | 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121 |
Karimah Es Sabar | director | C/O 8840 WILSHIRE BOULEVARD, 2ND FLOOR, BEVERLY HILLS CA 90211 |
Linda Marban | director, officer: CHIEF EXECUTIVE OFFICER | C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211 |
Dunbar George W Jr | director | C/O COMPETITIVE TECHNOLOGIES, INC., 777 COMMERCE DRIVE, SUITE 100, FAIRFIELD CT 06825 |
Karen Krasney | officer: EVP, GENERAL COUNSEL | C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211 |
Anthony Bergmann | officer: CHIEF FINANCIAL OFFICER | C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211 |
Louis Manzo | director | C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211 |
Cedars Sinai Medical Center | 10 percent owner | 8700 BEVERLY BLVD, LOS ANGELES CA 90048-1865 |
St. John Edward A. | 10 percent owner | 2560 LORD BALTIMORE DRIVE, BALTIMORE MD 21244 |
Leland Gershell | officer: Chief Financial Officer | C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK NY 10022 |
From GuruFocus
By PurpleRose PurpleRose • 07-19-2022
By Marketwired • 10-19-2023
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 11-07-2023
By Marketwired • 06-30-2023
By GuruFocusNews GuruFocusNews • 07-04-2022
By PurpleRose PurpleRose • 07-14-2022
By Marketwired • 09-29-2023
By GuruFocusNews GuruFocusNews • 07-07-2022
By Marketwired • 10-10-2023